Resource

 

 

 

 

 

 

 

 

 

 

 

JV/Alliance/Licence

Fieldfisher advises HANSAINVEST on a strategic partnership with ENOVA

27 Oct 2017

Fieldfisher advises HANSAINVEST Real Assets GmbH

Fieldfisher has advised HANSAINVEST Real Assets GmbH ("HANSAINVEST") on the legal aspects of a long-term strategic partnership with ENOVA Energiesysteme GmbH & Co. KG ("ENOVA") in the field of wind energy. The focus of the partnership is the acquisition of ongoing wind energy projects, as well as projects that are currently still in the approval/project planning phase.

Trowers & Hamlins advises Apache Capital on its joint venture for a luxury retirement village

23 Oct 2017

Trowers & Hamlins has advised long-standing client Apache Capital Partners (Apache Capital), on their joint venture deal with retirement housing company, Audley Group. The deal will see the development of a 13,750 sqm retirement village on Nightingale Lane, overlooking Clapham Common, London. The scheme has a gross development value of £125 million.

Apache Capital had already secured planning permission for the site it describes as bring a luxury retirement village, and they have joined with Audley to build the homes.

Macfarlanes advises Virgin Group on its investment in Hyperloop One

19 Oct 2017

Macfarlanes has advised the Virgin Group on its investment in Hyperloop One, and on the grant of a trade mark licence which will see the company rebranded as Virgin Hyperloop One.

Hyperloop One is developing a new mode of transport which will move cargo and passengers at high speed via electric propulsion through a low-pressure tube. The company is aiming to have operational systems in service by 2021.

Harmony Biosciences Acquires US Rights to Narcolepsy Drug That Is Currently Available in Europe

18 Oct 2017

McDermott Paris and US corporate and antitrust lawyers were counsel to French company Bioprojet SCR in structuring a collaborative agreement that gave biopharmaceutical company Harmony Biosciences the exclusive US right to develop, register and market a drug to treat adults suffering from narcolepsy.

CMS advises Chinese Electric Car Start-up AIWAYS on Joint Venture with the Sports Car Manufacturer Roland Gumpert

16 Oct 2017

The Chinese start-up company Jiangxi AIWAYS Entity Co., Ltd. has established a joint venture to develop electric sports cars with the sports car manufacturer Roland Gumpert. The joint venture will operate under the name Gumpert Aiways Automobile GmbH.

A CMS team led by partner Dr Oliver Wolfgramm provided AIWAYS with comprehensive legal advice on this joint venture.

Reed Smith advises Civil Aviation Authority in relation to Monarch Airlines insolvency

12 Oct 2017

Reed Smith LLP has advised the Civil Aviation Authority, in relation to the insolvency of Monarch Airlines and the regulator’s decisions on the airline’s Air Travel Organiser’s Licence (Atol) and its Operating Licence. 

Working with the CAA's own in-house legal team, Richard Spafford advised on licensing and regulatory issues and Charlotte Møller led a team advising on the insolvency law and contingency planning for the repatriation.

Greene King taps TLT for JV pub launch

10 Oct 2017

Greene King, the UK's leading pub retailer and brewer, has enlisted the support of TLT for its first joint venture, The Butcher's Tap.

The deal sees Greene King partner again with celebrated publican and two-Michelin star chef Tom Kerridge and also with butcher Andy Cook.

The project marks the first of Greene King’s joint venture concepts, an innovative new programme for its Pub Partners division that will see the company team up with the best entrepreneurs and innovators who have the courage to be bold and try something new.

Harmony Biosciences acquires US rights to Pitolisant from Bioprojet

06 Oct 2017

Biopharmaceutical company Harmony Biosciences, LLC (Harmony), a member of the Paragon Biosciences (Paragon) corporate family, announced today it has acquired the exclusive US right to develop, register and market the drug Pitolisant from French company Bioprojet SCR (Bioprojet), advised by McDermott Will & Emery.

Pitolisant has been recently approved by the European Medicines Agency (EMA) to treat adults suffering from narcolepsy.